Cupid Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Cupid Limited Receives CE (EU IVDR) Certification for HIV 1 & 2 and Hepatitis B IVD Test Kits, Expanding Global Market Access in Diagnostics.".
CUPID · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cupid Limited has received CE certification under the European Union's In Vitro Diagnostic Regulation (EU IVDR) for its HIV 1 & 2 and Hepatitis B IVD (in-vitro diagnostic) test kits. The CE mark is a mandatory regulatory requirement that allows the company to legally market and sell these diagnostic products across the European Union and other markets that recognize CE certification. This move expands Cupid's footprint in the global diagnostics segment, complementing its existing product portfolio. The certification was communicated to the exchanges via a press release dated January 28, 2026.
Positive for shareholders — this unlocks access to the large and tightly regulated EU diagnostics market, potentially driving new revenue streams and strengthening the company's international growth story in the medical diagnostics space.